Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study

At Four Weeks, Patients Treated with Mirikizumab Achieved Rapid and Clinically Meaningful Symptomatic Remission and Bowel Urgency Reduction Compared to Placebo INDIANAPOLIS , Feb. 18, 2022 /PRNewswire/ -- Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab